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Central nervous system control of energy balance affects susceptibility to obesity and diabetes, but how fatty
acids, malonyl-CoA, and other metabolites act at this site to alter metabolism is poorly understood. Pharmacological inhibition of fatty acid synthase (FAS), rate limiting for de novo lipogenesis, decreases appetite
independently of leptin but also promotes weight loss through activities unrelated to FAS inhibition. Here we
report that the conditional genetic inactivation of FAS in pancreatic β cells and hypothalamus produced lean,
hypophagic mice with increased physical activity and impaired hypothalamic PPARα signaling. Administration of a PPARα agonist into the hypothalamus increased PPARα target genes and normalized food intake.
Inactivation of β cell FAS enzyme activity had no effect on islet function in culture or in vivo. These results
suggest a critical role for brain FAS in the regulation of not only feeding, but also physical activity, effects that
appear to be mediated through the provision of ligands generated by FAS to PPARα. Thus, 2 diametrically
opposed proteins, FAS (induced by feeding) and PPARα (induced by starvation), unexpectedly form an integrative sensory module in the central nervous system to orchestrate energy balance.
*OUSPEVDUJPO
Higher organisms adapt to changes in energy needs by assimilating
peripheral hormonal and nutritional cues and integrating them in
the central nervous system (1, 2). Even subtle defects in this system have deleterious consequences since modest excess weight in
humans is associated with increased mortality (3, 4). The most
thermodynamically efficient strategy for weight loss is appetite
suppression, a difficult goal given the diversity of factors regulating food intake, ranging from amines and peptides to metabolites
and fatty acids (reviewed in ref. 5).
Fatty acid metabolism affects feeding behavior. Malonyl-CoA,
an intermediary substrate controlling fatty acid flux, and carnitine
palmitoyltransferase-1 (CPT-1), which allows fatty acids access to
mitochondria for β-oxidation, have been independently implicated in regulating appetite (6, 7). Pharmacological inhibition of fatty
acid synthase (FAS), the multifunctional enzyme that utilizes malonyl-CoA for the first committed step in fatty acid biosynthesis
(8), with the compound C75 produces anorexia and weight loss in
mice in the setting of increased malonyl-CoA (9). However, recent
studies indicate that these effects on malonyl-CoA alone may not
be sufficient to induce anorexia, as C75 also has an impact on the
sympathetic nervous system and metabolic mediators, including
PPARα and PPARγ coactivator-1 α (PGC1α) (10, 11). In addition,
Nonstandard abbreviations used: ACO, acyl-CoA oxidase; AgRP, agouti-related
protein; CART, cocaine-amphetamine–related transcript; CPT-1, carnitine palmitoyltransferase-1; FAS, fatty acid synthase; FASKO mice, mice lacking FAS in pancreatic
β cells and a diffuse neuronal population within the hypothalamus; Glut2, glucose
transporter 2; MCD, malonyl-CoA decarboxylase; MCH, melanin-concentrating
hormone; NPY, neuropeptide Y; Pdx-1, pancreatic duodenal homeobox-1; POMC,
proopiomelanocortin; RIPCre mice, mice expressing Cre under the control of the rat
insulin 2 promoter.
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CNS glucose metabolism is required for the anorexic actions
of C75 (12). How multiple disparate events related to fatty acid
metabolism in the CNS coordinate energy balance is uncertain.
Previous studies have linked appetite and pancreatic β cell function. Chronic i.c.v. insulin infusion reduces food intake and body
weight (13). Genetic disruption of insulin receptor substrate 2 in
β cells and the hypothalamus using rat insulin 2 promoter Cre
(RIPCre) transgenic mice mated with floxed insulin receptor substrate 2 mice increases appetite as well as body weight and causes
diabetes (14, 15). Constitutive activation of CPT-1 in pancreatic
islets suppresses glucose-stimulated insulin secretion (16) whereas
inhibition of CPT-1 in the hypothalamus (which increases longchain fatty acyl-CoAs) decreases hepatic gluconeogenesis and food
intake (17). Since many of the same factors appear to regulate food
intake and β cell function, a common mechanism could integrate
glucose metabolism and feeding behavior.
FAS is one such potential integrative mediator. It is regulated
by glucose, insulin, amino acids, fatty acids, leptin, and other
metabolites directly involved in energy balance (18–20). FAS
is increased in animal models of obesity and insulin-resistant
diabetes (21), and a sequence variant in FAS is associated with
altered adiposity in humans (22). FAS expression is ubiquitous
and essential for life since global inactivation of the FAS gene
in mice is embryonic lethal at the preimplantation stage (23).
Recent studies using liver-specific FAS knockout mice suggest
that products of the FAS reaction (as yet unidentified) regulate
hepatic glucose and lipid metabolism by serving as endogenous
activators of the nuclear receptor PPARα (24). These findings
and others (23, 25) suggest that de novo lipogenesis produces a
distinct regulatory pool of fatty acids.
To determine whether FAS in pancreatic β cells and the CNS
affects glucose metabolism and feeding, we mated floxed FAS mice
(24) with RIPCre mice (26). We found that FAS is not important
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MPY1TJUFT CMBDLBSSPXIFBET GMBOLJOHFYPOTm HSBZCPYFT XFSF
NBUFEXJUI3*1$SFBOJNBMTUPZJFME'"4,0NJDFBOEUIFJSMJUUFSNBUF
DPOUSPMT 85 GMPYFENJDFXJUIPVU$SF  #BOE$ 1$3BOBMZTJT
%/"GSPN'"4,0JTMFUT * BOEIZQPUIBMBNVT ) QSPEVDFEBCQ
QSPEVDU # MBOF$ MBOF VTJOHQSJNFST" GPSXBSEBSSPX BOE#
SFWFSTFBSSPX JO" JOEJDBUJOHBQQSPQSJBUFEFMFUJPOPGFYPOTmPG
UIF'"4HFOF5IFQSPEVDUXBTBCTFOUJOUIFJTMFUTBOEIZQPUIBMBNVT
JO85 # MBOF$ MFGUQBOFM MBOF BTXFMMBTJOFQJEJEZNBMGBU
QBET '"5 LJEOFZ ,*% MJWFS - DFSFCSBMDPSUFY $ BOEDFSFCFMMVN
$ SJHIUQBOFM PG85BOE'"4,0NJDF % 2VBOUJUBUJWF351$3PG
UJTTVFTGSPN3*1$SFBOE'"4,0NJDFTIPXFE$SFFYQSFTTJPOPOMZ
JOJTMFUTBOEIZQPUIBMBNVT & %PSTBMBOEWFOUSBMWJFXTPGXIPMF
CSBJOGSPN'"4,0BOE85NJDFNBUFEXJUI304"BOJNBMTBOE
TUBJOFEGPSβHBMBDUPTJEBTF CMVFTUBJOJOH JOEJDBUJWFPG$SFFYQSFT
TJPO VQQFSQBOFM 3PCVTUFYQSFTTJPOPG$SFXBTMBSHFMZSFTUSJDUFE
UPUIFIZQPUIBMBNVTPG'"4,0NJDF NJEEMFBOEMPXFSQBOFMT XJUI
XFBLFYQSFTTJPOJOUIFTUSJBUVN0SJHJOBMNBHOJGJDBUJPO × NJEEMF
QBOFMT × MPXFSQBOFMT × TUSJBUVN 0UIFSCSBJOSFHJPOTIBE
OPCMVFTUBJOJOH 'BOE( *OTJUVIZCSJEJ[BUJPO"3$ BSDVBUFOVDMFVT
7.) WFOUSBMNFEJBMIZQPUIBMBNVT"NZH BNZHEBMB$1 DBVEBUF
QVUBNFO TUSJBUVN )C IBCFOVMB$"   IJQQPDBNQVTBSFBT$" 
$" $"%( IJQQPDBNQVTEFOUBUFHZSVT.$ NPUPSDPSUFY1$ 
QZSJGPSNDPSUFY4$ TFOTPSZDPSUFY5IBM UIBMBNVT [POBJODFSUB 
4/ TVCTUBOUJBOJHSB7 UIJSEWFOUSJDMF ) '"4N3/"FYQSFTTJPOJO
UIFIZQPUIBMBNVTCZRVBOUJUBUJWF351$3 * '"4FO[ZNFBDUJWJUZJO
JTPMBUFEJTMFUT MFGUQBOFM FQJEJEZNBMGBUQBET BOEMJWFS SJHIUQBOFM 
+ %FUFSNJOBUJPOPGNBMPOZM$P" .BM$P" DPOUFOUJOJTPMBUFEJTMFUT
, .BMPOZM$P"DPOUFOUJOUIFIZQPUIBMBNVTPGIPVSGBTUFE GBTU 
BOEIPVSGBTUFEmIPVSSFGFE SFGFE NJDF'PS%BOE(m, SFTVMUT
BSFNFBO4&.PGmBOJNBMTQFSHSPVQ 1 1
DPNQBSFEXJUIDPSSFTQPOEJOH85NJDF

for pancreatic β cell function but is crucial for coordinating feeding behavior by activating PPARα in the brain.
3FTVMUT
Generation of pancreatic β cell and hypothalamic FAS knockout mice. By
crossing mice homozygous for the FAS loxP allele (24) with RIPCre mice, we generated FASKO (FAS knockout) mice (Figure 1),
which were born at the expected frequency. There was no effect of
genotype on either litter size or birth weights. FAS gene rearrangement was confirmed by PCR using primers (24) that yield a 317-bp
product when exons 4–8 of the gene are deleted (Figure 1A) and
was restricted to islets (Figure 1B) and hypothalamus (Figure 1C).
FAS was not rearranged in other peripheral tissues (Figure 1B), the
cerebral cortex (Figure 1C), or the cerebellum (Figure 1C) in WT
or FASKO animals.
We confirmed previous reports (14, 15, 27) of both pancreatic
β cell and hypothalamic Cre expression with this RIPCre model
in 2 ways. First, Cre mRNA was detected by quantitative RT-PCR
only in the hypothalamus and islets of RIPCre and FASKO mice
(Figure 1D). Second, we crossed the FASKO mice with ROSA26
animals, a model that allows expression of β-galactosidase in the
presence of Cre recombinase (28). Expression of β-galactosidase
was present, as expected, in pancreatic β cells (not shown). Strong
expression of β-galactosidase was also present in a diffuse population of hypothalamic neurons and weakly within the striatum
(caudate putamen) in FASKO brains (Figure 1E), a pattern that
is consistent with previous reports (14, 15, 27, 29). However, in
situ hybridization for FAS message showed that its expression was
The Journal of Clinical Investigation

unaffected by genotype in the striatum, substantia nigra, or other
brain regions analyzed, except within the hypothalamus of FASKO
mice around the arcuate nucleus and the ventral medial hypothalamus (Figure 1, F and G). The decrease in FAS expression in the
hypothalamus was further quantified and confirmed by quantitative RT-PCR (Figure 1H). The actual degree of neuronal FAS suppression was probably greater than shown in Figure 1H since these
measurements include glial cells, which would not be expected to
show gene rearrangement and decreased expression. Brain weight
(0.43 ± 0.02 g WT versus 0.41 ± 0.02 g FASKO; P = NS, n = 5) and
overall brain morphology were also similar between genotypes.
Two other lines of evidence indicated that FAS was disrupted in
pancreatic β cells and hypothalamus. First, FAS enzyme activity
was decreased and malonyl-CoA levels were increased in isolated
FASKO islets (Figure 1, I and J). Malonyl-CoA, a FAS substrate,
would be expected to rise with FAS disruption. FAS enzyme activity
was unaffected in FASKO epididymal fat and liver (Figure 1I, right
panel). Second, hypothalamic malonyl-CoA content in the FASKO
mice was significantly elevated even in the fasted state; levels under
these conditions should be low, as seen in fasted WT littermates
(Figure 1K). Collectively, these results are consistent with selective
inactivation of FAS in pancreatic β cells and the hypothalamus.
Pancreatic β cell function in FASKO mice. Although recent data suggest that Cre expression alone may have nonspecific effects on
β cell function (30), we found no β cell phenotype in FASKO mice.
Loss of FAS enzyme activity in FASKO islets (Figure 1I) had no
effect on glucose and insulin levels during glucose tolerance testing (Figure 2, A–C). When islets were isolated from these mice
and stimulated with glucose in culture, there was no difference in
insulin secretion (Figure 2D). Insulin content of whole pancreas as
well as isolated islets was unaffected by the deletion of β cell FAS
(Figure 2, E and F). Islets from FASKO mice exhibited normal distribution of non-β cells at the periphery and insulin-positive cells
in the core (Figure 2G). Morphometry showed similar β cell mass
(Figure 2H) and islet size distribution (not shown) in FASKO and
WT mice. Expression of genes involved in glucose sensing and islet
function, such as glucokinase (Gck), glucose transporter 2 (Glut2),
and pancreatic duodenal homeobox-1 (Pdx-1), was unaltered by
islet FAS inactivation (Figure 2I). Together, these results show that
FAS is not required for β cell function in adult mice.
Feeding behavior and energy balance in FASKO mice. FASKO mice
weighed less, but were not runted, compared with their WT littermates (Figure 3, A and B). Their decreased body weight was
due to decreased adiposity without a genotype effect on percentage of lean body mass (Figure 3C). Adiposity is determined by
the balance between caloric intake and expenditure. Both were
affected in FASKO mice. Freely feeding FASKO mice ate 17% less
than control (WT and RIPCre) animals (Figure 4A). To determine
whether this hypophagia was dependent on feeding state, we
studied the response of FASKO mice to 24 hours of food deprivation. Compared with ad libitum baseline levels, food intake was
significantly attenuated at 4 hours and 24 hours after refeeding
(Figure 4B) in FASKO mice, confirming the hypophagic effect
of CNS FAS disruption. This genetic alteration did not produce
visceral illness or aversive behavior, as FASKO mice had normal water intake (2.03 ± 0.94 versus 1.98 ± 1.05 ml/24 h in WT;
P = NS, n = 20), body temperature, stool mass and consistency,
pain threshold (assessed using the hot plate test at 55°C, not
shown), and corticosterone concentration (Table 1). Serum glucose, insulin, free fatty acids, triglycerides, and cholesterol levels
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under ad libitum chow-fed and 24-hour–fasted conditions were
also similar between genotypes (Table 1).
FASKO animals exhibited increased oxygen consumption under
both fed (Figure 4C) and fasted conditions (Figure 4D). When animals were tested over a 1-hour period using a computerized photobeam system, FASKO mice showed significantly increased locomotor activity in terms of both total beam breaks (Figure 4E) and
ambulations (whole-body movements) (Figure 4F). They also had
increased ambulation over a 24-hour period (Figure 4G), with the
greatest differences being manifested during the dark phase, the
same time period during which maximal differences in oxygen consumption were seen (Figure 4C). Increased oxygen consumption in
FASKO animals was mainly due to increased physical activity rather
than intrinsically elevated metabolism in peripheral tissues, since
substrate oxidation rate, substrate preference (respiratory exchange
ratio), heat generation, and cold-induced thermogenesis were all
unaffected by genotype (Table 2). We sought further confirmation
of increased physical activity by using an infrared sensing technique to measure home-cage activity over 3 days (Figure 4H). This
increase in activity was seen only in the FASKO mice and not in the
control (WT and RIPCre) animals (Figure 4H). Together with hypophagia (Figure 4A), these data suggest that the observed phenotype
is due to FAS inactivation and not a nonspecific effect of Cre.
FASKO animals also made more entries (Figure 4I), spent more
time (Figure 4J), and traveled a greater distance (Figure 4K) in the
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center of the open field as compared with WT controls. These
differences might reflect altered emotionality and not merely a
generalized hyperactive state because the distance traveled in the
periphery of the same open-field arena was similar between genotypes (Figure 4L).
To determine whether hypophagia, increased physical activity,
or both were responsible for lower body weight in FASKO animals,
we performed pair-feeding experiments. When WT mice were food
restricted by pair-feeding to FASKO animals for 7 days, the change
in their body weight and percentage of fat mass was nearly identical to that of freely fed FASKO mice (Figure 5, A and B). Percentage of lean mass remained unaffected by genotype or pair feeding
(Figure 5C). Physical activity in the WT pair-fed mice remained the
same as in ad libitum–fed control mice (WT-Ctrl) and was lower
than that of FASKO animals (Figure 5D). These results suggest
that decreased food intake is largely responsible for decreased adiposity in FASKO mice. However, they do not eliminate the possibility that, over the long term, increased physical activity of these
mice also contributes to their decreased adiposity.
Pair feeding WT mice with FASKO animals further decreased
hypothalamic malonyl-CoA content relative to that of freely fed
control animals, an appropriate physiologic response to fasting
(Figure 5E). Serum metabolites and hormones in the WT pair-fed
mice confirmed the relative fasted state (Table 1). Since, by design,
food intake in FASKO and pair-fed WT mice was the same, higher
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3FTVMUT BSF GSPN m NJDF QFS
HFOPUZQFQFSTFY 1WFSTVT
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UPXFFLPME85BOE'"4,0NBMF
NJDFVTJOHEVBMFOFSHZYSBZBCTPSQUJ
PNFUSZSFQSFTFOUFEBTBCTPMVUFNBTT
UPQQBOFM BOEBTQFSDFOUBHFPGUPUBM
CPEZNBTT CPUUPNQBOFM &BDICBS
SFQSFTFOUTUIFNFBO4&.PGm
BOJNBMTQFSHFOPUZQF 1DPN
QBSFEXJUI85

hypothalamic malonyl-CoA content in the FASKO animals (Figure
5E) suggests that hypophagia in these animals was a consequence
of hypothalamic FAS inactivation.
Feeding behavior is controlled in part by orexigenic and anorexigenic neuropeptides within the arcuate nucleus of the hypothalamus, where signals such as insulin and leptin are integrated (1,
2). In situ hybridization revealed suppression of mRNAs for the

orexigenic neuropeptides agouti-related protein (AgRP) and neuropeptide Y (NPY) and induction of mRNAs for the anorexigenic
neuropeptides cocaine-amphetamine–related transcript (CART)
and proopiomelanocortin (POMC) in FASKO as compared with
WT arcuate nucleus (Figure 6, A and B). Many hypothalamic
areas, including the paraventricular nucleus and the lateral hypothalamus, are supplied by axons from the NPY/AgRP neurons in

'JHVSF
)ZQPUIBMBNJD'"4JOBDUJWBUJPOEFDSFBTFTGPPEJOUBLF JODSFBTFTNFUBCPMJDSBUFBOEQIZTJDBMBDUJWJUZ BOEBMUFSTCFIBWJPS " "EMJCJUVNEBJMZ
GPPEJOUBLFJODPOUSPM 85<MPYMPY$SFm>BOE3*1$SF BOE'"4,0NJDF O  # $IBOHFJOGPPEJOUBLFXJUISFGFFEJOHBGUFSBIPVSGBTU
SFMBUJWFUPBEMJCJUVNCBTFMJOFMFWFMT Om #8 CPEZXFJHIU $m% 0YZHFODPOTVNQUJPO 70 CZJOEJSFDUDBMPSJNFUSZEVSJOHBIPVS
MJHIU BNmQN BOEIPVSEBSL QNmBN DZDMFJOGSFFMZGFEBOJNBMTBOEGPMMPXJOHBIPVSGBTU & "TTFTTNFOUPGMPDPNP
UPSBDUJWJUZEFUFSNJOFECZUPUBMCFBNCSFBLT ' "NCVMBUJPOTJOBOPQFOGJFMEBSFOBXFSFSFDPSEFEPWFSBIPVSBOE ( IPVSQFSJPEVTJOHB
DPNQVUFSJ[FEQIPUPCFBNTZTUFN ) )PNFDBHFBDUJWJUZXBTRVBOUJGJFEVTJOHJOGSBSFETFOTPSTPWFSBEBZQFSJPE *m- "TTFTTNFOUPGPQFO
GJFMECFIBWJPST JODMVEJOHUPUBMDFOUFSFOUSJFT UJNFTQFOUJOUIFDFOUFS EJTUBODFUSBWFMFEJOUIFDFOUFS BOEEJTUBODFUSBWFMFEJOUIFQFSJQIFSZPG
UIFUFTUBSFOB'PS$m- mBOJNBMTQFSHFOPUZQFXFSFVTFE"MMHSBQITSFQSFTFOUNFBO4&. 1DPNQBSFEXJUI85MJUUFSNBUFT
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5BCMF
Serum chemistries and hormones in free-feeding, pair-fed (PF), and 24-hour fasted WT and FASKO mice

cycle caused an increase in
food intake comparable to
WT levels over the 24-hour
refeeding period (Figure
Free feeding
Fast (24 hour)
8, A and B). Differences in
FASKO (n = 8) WT-PF (n = 8)
WT (n = 8) FASKO (n = 8)
Parameters
WT (n = 8)
body weight change between
A
107.1 ± 6.1
97.5 ± 10.6
Glucose (mg/dl)
156.5 ± 4.1
144.6 ± 7.2
119.1 ± 7.8
FASKO and WT mice were
Free fatty acids (mEq/l)
0.77 ± 0.05
0.74 ± 0.07
1.27 ± 0.07A
2.29 ± 0.12
1.99 ± 0.24
also abolished by 4 hours
A
Triglycerides (mg/dl)
95.6 ± 14.1
104.2 ± 15.9
67.4 ± 5.1
37.4 ± 5.1
58.2 ± 11.1
(Figure 8, A and B), reflectCholesterol (mg/dl)
105.2 ± 4.4
88.6 ± 6.1
89.0 ± 5.2
79.0 ± 5.2
68.5 ± 4.9
ing increased food intake
Insulin (ng/ml)
1.13 ± 0.25
1.04 ± 0.21
0.65 ± 0.06A
0.51 ± 0.10
0.40 ± 0.12
in the FASKO animals with
Leptin (ng/ml)
1.37 ± 0.24
1.69 ± 0.33
ND
0.53 ± 0.14
0.77 ± 0.13
i.c.v. PPARα agonist treatCorticosterone (μg/dl)
3.6 ± 0.5
3.9 ± 0.7
ND
ND
ND
ment. As compared with
4FSVNXBTPCUBJOFEGSPNUPXFFLPMENBMFNJDF&BDIWBMVFSFQSFTFOUTNFBO4&."1DPNQBSFEXJUI
hypophagic vehicle-treated
GSFFMZGFFEJOH'"4,0BOJNBMT851' 85NJDFQBJSGFEUPGSFFMZGFE'"4,0BOJNBMTGPSEBZT/% OPUEFUFSNJOFE
FASKO mice, Wy14,643treated FASKO animals had
higher serum glucose and
the arcuate nucleus (31). Therefore, we also assessed melanin-con- insulin concentrations and lower free fatty acid levels (Table 3),
centrating hormone (MCH) and orexin (OX) mRNAs in the lateral consistent with their increased food intake after the 23.5-hour fast
hypothalamus and CART mRNA in the paraventricular nucleus. In (Figure 8B). Water intake was not affected by either vehicle or drug
contrast to changes in neuropeptide expression seen in the arcu- treatment (not shown).
If FAS affects feeding through PPARα, CNS administration of
ate nucleus, MCH and OX mRNA levels in the lateral hypothalamus
(Figure 6, A and B) and CART expression in the paraventricular Wy14,643 should restore not only food intake but also expression
nucleus (not shown) were similar between FASKO and control of PPARα target genes. PPARα, ACO, CPT-1, and MCD mRNAs in
animals. Our previous studies (32) showed that pair feeding nor- the hypothalamus were induced in FASKO mice at the end of the
mally increases NPY and decreases CART and POMC expression, a refeeding period (Figure 8C). Wy14,643 given i.c.v. also lowered
normal physiological response to fasting (33). In contrast, despite hypothalamic malonyl-CoA (Figure 8D), suggesting that hypotheir hypophagia, FASKO mice have a hypothalamic neuropeptide thalamic PPARα signaling regulates malonyl-CoA, presumably
expression profile (at least in the arcuate nucleus) characteristic of through the induction of MCD (36). To confirm that Wy14,643
the fed state.
treatment increased food intake in FASKO mice, we subjected
FAS activation of brain PPARα coordinates feeding behavior. While mice to a crossover protocol in which animals previously treated
hypophagic FASKO mice resemble C75-treated WT mice (9, 31), with the drug were given vehicle after a 1-week washout period.
C75 also affects the sympathetic nervous system and mediators Withdrawal of PPARα activation in FASKO mice returned feeding
such as PPARα (10, 11). Since hepatic FAS is required for PPARα and body weight to baseline levels (Figure 8, E and F).
To further confirm that PPARα agonist treatment rescues hypoactivation (24), we hypothesized that FAS regulates feeding
through PPARα. We first studied the effects of hypothalamic FAS phagia in FASKO mice, we injected Wy14,643 into the ventral
disruption on PPARα expression and its target genes. In contrast hypothalamus by bilateral stereotaxic injection. To verify approto limited data regarding the presence of PPARα in the hypothala- priate delivery to the targeted area, Evans blue, an inert dye, was
mus (34), we consistently detected PPARα message by quantita- coinjected with the drug, and brain sections were examined for
tive RT-PCR and found no genotype effect (Figure 7A). However, the presence of the dye. As illustrated in Figure 9A, 24 hours after
message levels of 3 genes known to be induced by PPARα (35, 36), bilateral stereotaxic injection, dye was detected in the ventral hypoacyl-CoA oxidase (ACO), CPT-1, and malonyl-CoA decarboxylase (MCD, which lowers malonyl-CoA levels), were decreased
by approximately 50% in FASKO compared with WT hypo5BCMF
thalamus (Figure 7A). All of these genes were appropriately
Metabolic parameters in WT and FASKO mice
induced in WT mice pair fed with FASKO animals, reflecting the normal physiologic response to fasting (Figure 7A).
Parameters
WT
FASKO
These data show impaired hypothalamic PPARα activation
SOR (pmol 14C-palmitate oxidized/mg/h)
0.89 ± 0.15
1.01 ± 0.18
in hypophagic FASKO animals.
Respiratory exchange ratio-fed state
0.83 ± 0.09
0.81 ± 0.07
If decreased hypothalamic PPARα signaling caused by FAS
Respiratory exchange ratio-fasted state
0.71 ± 0.05
0.71 ± 0.06
inactivation suppresses food intake (Figure 4B), then adminHeat-fed state (kcal/h)
0.61 ± 0.04
0.56 ± 0.07
Heat-fasted state (kcal/h)
0.49 ± 0.05
0.47 ± 0.04
istration of Wy14,643 (a potent PPARα agonist) near the
VO2 at 4°C (ml/g0.75/h)
16.69 ± 0.11
16.90 ± 0.10
hypothalamus should prevent hypophagia. Since there were
no previous reports of i.c.v. treatment with Wy14,643, we per*OWJUSP$QBMNJUBUFPYJEBUJPOSBUFGSPNMJWFSTMJDFTPGUPXFFLPME85
formed dose-response studies to minimize the likelihood of
BOE'"4,0NBMFNJDF O #PUIHFOPUZQFTTIPXFEBQQSPQSJBUFTVCTUSBUF
TXJUDIJOHGSPNDBSCPIZESBUFTUPGBUEVSJOHGBTUJOHBTEFUFSNJOFECZSFTQJSB
nonspecific effects or visceral illness caused by the drug. The
UPSZFYDIBOHFSBUJPBOEBOBQQSPQSJBUFEFDSFBTFJOIFBUHFOFSBUJPOXJUI
lowest effective i.c.v. dose that did not adversely affect food/
GBTUJOH FBDINFBTVSFECZJOEJSFDUDBMPSJNFUSZJOBEMJCJUVNGFEBOEIPVS
water intake and body weight in WT animals was 15 μg (FigGBTUFE85BOE'"4,0NJDF O 0YZHFODPOTVNQUJPO 70 XBTEFUFS
ure 7, B–D). Administration of this dose i.c.v. to 23.5-hour
NJOFECZJOEJSFDUDBMPSJNFUSZJOBOJNBMTNBJOUBJOFEBU$GPSNJOVUFT
O 403 TVCTUSBUFPYJEBUJPOSBUF
fasted FASKO mice 30 minutes before the onset of the dark
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thalamus adjacent to and below the third ventricle, a typical pattern for bilateral stereotaxic injections at this site.
As FASKO mice were hypophagic under ad libitum–fed conditions (Figure 4A), we hypothesized that restoration of PPARα
signaling in freely fed animals would also prevent the hypophagia. Thirty minutes before the onset of the dark cycle, 10 μg of
Wy14,643 was delivered directly into the ventral hypothalamus
by bilateral stereotaxic injection, which resulted in increased

food intake in FASKO mice by 12 hours that was significantly more than in WT at 24 hours (Figure 9, B and C). The body
weight change was higher in FASKO mice after intrahypothalamic
Wy14,643 injection as compared to vehicle-treated animals at the
12-hour and 24-hour time points (Figure 9, B and C), reflecting
increased food intake and reversal of the baseline hypophagia. As
with i.c.v. experiments, PPARα and its target genes ACO, CPT-1,
and MCD were also induced after intrahypothalamic administra-

'JHVSF
*OTJUVIZCSJEJ[BUJPOBOBMZTJTPGIZQPUIBMBNJDPSFYJHFOJDBOEBOPSFYJHFOJDOFVSPQFQUJEFT "BOE# *OTJUVIZCSJEJ[BUJPOTIPXJOHEFDSFBTFE
"H31BOE/1: CVUJODSFBTFE$"35BOE10.$N3/"FYQSFTTJPOXJUIJOUIFBSDVBUFOVDMFVTPGGSFFMZGFE85BOE'"4,0NJDF/PFGGFDU
PGHFOPUZQFJTTFFOPON3/"MFWFMTPG.$)BOEPSFYJO 09 XJUIJOUIFMBUFSBMIZQPUIBMBNVT5IFSFDUBOHMFTJOEJDBUFUIFBSFBBOBMZ[FECZ
EFOTJUPNFUSZUPRVBOUJGZUIFN3/"BCVOEBODFJO#0SJHJOBMNBHOJGJDBUJPO ¤"MMSFTVMUTBSFNFBO4&.PGBOJNBMTQFSHSPVQGSPN
JOEFQFOEFOUFYQFSJNFOUT 1DPNQBSFEXJUI85MJUUFSNBUFT
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could activate PPARα and reverse hypophagia in FASKO mice, we fed
these animals a high-fat diet (42%) for 2 weeks (Figure 11). Though
food intake in both genotypes was decreased compared with their
respective baseline levels during this relatively short high-fat feeding period (Figure 11B), hypophagia in FASKO animals persisted
whether expressed as absolute intake per day (Figure 11A) or as percentage change from chow baseline (Figure 11B). This intervention
also failed to restore the impaired hypothalamic PPARα signaling
(Figure 11C). FASKO mice remained hypophagic even after 10 weeks
of high-fat feeding (not shown). Together, these results suggest that
fatty acids synthesized by FAS but not those provided by dietary fat
activate PPARα in the brain to affect feeding behavior.

tion of Wy14,643 (Figure 9D). However, intrahypothalamic treatment resulted in higher expression of CPT-1 and MCD mRNA levels in FASKO as compared with WT mice (Figure 9D) at the end of
the 24-hour feeding period, coincident with their increased food
intake (Figure 9C).
Peripheral administration of Wy14,643 at much higher doses
is reported to induce anorexia in mice (37). Although effective at
reversing hypophagia with CNS administration, the same dose of
Wy14,643 given i.p. did not affect food intake or body weight in
FASKO mice (Figure 10, A and B). Control mice also maintained
their baseline food intake and body weight. As expected, i.p. injection of the PPARα agonist induced PPARα and its target genes in
the liver (Figure 10C) and jejunum (not shown) but had no effect
on the same genes in the hypothalamus (Figure 10D), confirming
that CNS activation of PPARα is required to increase food intake
in FASKO animals.
Long-chain fatty acids may serve as ligands for PPARα and are
derived from dietary fat or generated de novo by the FAS reaction.
To determine whether supplying high levels of fatty acids in the diet
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%JTDVTTJPO
FAS is an attractive potential target for obesity therapies because
it is regulated by major mediators of energy balance and controls
steady-state levels of substrates affecting food intake. However,
direct evidence implicating FAS in feeding behavior is lacking
since pharmacological inhibitors of FAS such as C75 have complex
effects that include activation of the sympathetic nervous system.
Our generation of mice with genetic inactivation of FAS in the
hypothalamus and β cell serendipitously resulted in animals with
hypophagia and altered behavior with no apparent β cell phenotype, allowing us to implicate brain FAS in energy homeostasis
through its activation of the nuclear receptor PPARα.
The absence of a β cell phenotype in these mice was unexpected.
De novo lipogenesis through malonyl-CoA is important for insulin
secretion in HIT cells, a β cell line (38). The malonyl-CoA/CPT-1
interaction contributes to a metabolic signaling network controlling insulin secretion in INS(832/13) cells (16). In contrast with
these studies in cell lines, our in vivo results using islets with the
loss of FAS enzyme activity (Figure 1I) and increased malonyl-CoA
content (Figure 1J) indicate that FAS is not required for β cell function (Figure 2).
FASKO mice had less adiposity, decreased food intake, and
increased activity (Figures 3 and 4), prompting the evaluation
of non-β cell tissues affecting energy homeostasis. We detected
extraislet Cre expression within the hypothalamus and caudate
putamen (striatum) (Figure 1E), consistent with results of others using the rat insulin 2 promoter to drive Cre (14, 15, 27, 29).
However, analysis of various brain regions for FAS gene rearrangement and mRNA expression showed that FAS inactivation was
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largely restricted to the hypothalamus (Figure 1, B–H). Given the ase (41) and decrease malonyl-CoA levels, since malonyl-CoA is the
absence of an effect on β cell function in FASKO mice, it is likely product of the acetyl-CoA carboxylase reaction.
In the current work, we establish a basis for the coordinate reguthat FAS deletion in the hypothalamus is responsible for the lean
phenotype. Pair-feeding experiments (Figure 5) indicated that the lation of these interrelated mediators. FASKO mice lack normal
decreased adiposity in FASKO mice was mostly due to their rela- hypothalamic PPARα signaling (Figure 7A), resulting in hypophative hypophagia rather than increased physical activity. However, gia with increased malonyl-CoA content (Figure 1K and Figure 5E)
a minor contribution of physical activity to the lean phenotype and decreased expression of CPT-1 (Figure 7A and Figure 8C) in the
is plausible given that, despite the relative food restriction of WT hypothalamus. Intrahypothalamic and i.c.v. (but not i.p.) adminmice, a nonsignificant trend toward increased adiposity persisted istration of Wy14,643 restored hypothalamic PPARα signaling by
(Figure 5B). There is precedence for a link between hypothalamic inducing CPT-1 and MCD (Figure 8C and Figure 9D) and decreasFAS and increased food intake. Pharmacologic activation of the ing malonyl-CoA content (Figure 8D), which increased food intake
cannabinoid receptor 1 promotes feeding in
association with induction of hypothalamic
5BCMF
FAS gene expression (39).
Effect of i.c.v. administration of Wy14,643 on serum chemistries and hormones
Direct evidence for hypothalamic FAS
mediation of food intake helps unify previous
Vehicle
Wy14,643
observations regarding the role of fatty acid
metabolism in CNS control of bioenergetics.
FASKO (n = 7)
WT (n = 10) FASKO (n = 10)
Parameters
WT (n = 7)
Increased neuronal malonyl-CoA content, inhi171.2 ± 9.2
168.9 ± 10.5B
Glucose (mg/dl)
165.8 ± 5.8
128.6 ± 2.3A
bition of CPT-1 activity, and the accumulation
Free fatty acids (mEq/l) 0.38 ± 0.04
0.72 ± 0.04A
0.31 ± 0.05
0.40 ± 0.01B
of long-chain fatty acids and their esters have
Triglycerides (mg/dl)
96.6 ± 17.2
99.2 ± 14.0
88.7 ± 8.9
92.5 ± 16.1
been independently reported to suppress appeCholesterol (mg/dl)
92.5 ± 11.3
93.1 ± 7.0
86.4 ± 6.7
86.0 ± 4.5
tite (6, 7, 17, 40). These biologic variables are
Insulin (ng/ml)
4.01 ± 1.4
1.34 ± 0.57A
3.28 ± 1.6
3.01 ± 1.5B
interrelated in complex ways. High malonylLeptin (ng/ml)
1.64 ± 0.24
2.01 ± 0.34
1.66 ± 0.29
1.82 ± 0.43
CoA levels inhibit CPT-1 activity. Decreased
8Z  μH XBTJOKFDUFEJDWBGUFSBIPVSGBTUBOEBOJNBMTXFSFSFGFEGPSIPVST 
CPT-1 activity impairs fatty acid metabolism,
BUUIFFOEPGXIJDITFSVNXBTPCUBJOFEBOEBOBMZ[FE&BDIWBMVFSFQSFTFOUTNFBO4&.
causing the accumulation of long-chain fatty
GSPNUPXFFLPMENBMF85BOE'"4,0NJDF"1WFSTVTWFIJDMFUSFBUFE85
#1WFSTVTWFIJDMFUSFBUFE'"4,0NJDF
acyl-CoAs (7) that inhibit acetyl-CoA carboxylThe Journal of Clinical Investigation
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(Figure 8B and Figure 9C). Fatty acids provided in a high-fat diet
failed to correct impaired hypothalamic PPARα signaling (Figure 11C) or reverse hypophagia in FASKO animals (Figure 11A).
Therefore, fatty acids synthesized by FAS appear to activate PPARα
in the CNS to coordinate feeding behavior. These results are consistent with the model shown in Figure 12. FAS, known to be
regulated by several metabolites (glucose, amino acids, fatty acids,
insulin, and leptin) involved in energy balance (8, 18–20), senses
nutritional status in the CNS and orchestrates fatty acid metabolism to affect feeding behavior through the nutritionally regulated
nuclear receptor PPARα.
Why the administration of the PPARα agonist to WT animals does
not further increase food intake is unclear. Activating PPARα in an
animal with normal PPARα signaling (as opposed to FASKO animals with impaired PPARα activation) may prompt compensatory
changes in the expression of regulatory factors in an attempt to control food intake. In support of this notion, NPY and AgRP knockout
mice do not exhibit expected decreases in food intake (42). There is
no effect on food intake in whole-body PPARα null mice (43).
In addition to their hypophagia, FASKO mice had increased
oxygen consumption due to enhanced physical activity rather
than elevation of intrinsic metabolism in peripheral tissues (Figure 4 and Table 2). These phenotypes are strikingly similar to
those of MCH and MCH receptor knockout mice, which are also
hypophagic, lean, and hyperactive (44, 45). In our model, MCH
mRNA levels in the lateral hypothalamus were unaffected by genotype (Figure 6), but we cannot rule out effects on MCH protein
levels or MCH receptor signals contributing to the hyperactive
phenotype of FASKO mice.
FASKO animals also appeared to manifest decreased anxiety-like
behavior, as demonstrated by their increased number of entries,
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time spent, and distance traveled in the center of an open-field
arena (Figure 4, I–K). This behavioral change was unexpected,
since anorexia is commonly associated with increased anxiety-like
emotionality, as occurs with central infusion of corticotrophinreleasing factor (46) or glucagon-like peptide 1 (47). Rimonabant,
a cannabinoid receptor 1 receptor antagonist, causes weight loss
in humans, complicated by anxiety and depression (48). Unlike
these interventions, interrupting the hypothalamic FAS-PPARα
axis suppresses appetite and increases physical activity without
producing concomitant increases in anxiety-like behaviors, ideal
side effects for treating human obesity.
In summary, FAS is not required for pancreatic β cell function
but is critical for the regulation of feeding behavior through the
activation of PPARα, likely in the hypothalamus. It might seem paradoxical that PPARα, a transcription factor that evolved to respond
to starvation, is regulated by FAS, an enzyme activated by feeding.
We speculate that it is precisely because of their opposite roles that
these factors coordinate feeding behavior by forming a negative
feedback loop between availability of nutrients and their metabolism. The FAS-PPARα axis (Figure 12) may thus represent an evolutionary adaptation to maintain energy homeostasis in response to
2 of the most primordial stimuli, feeding and starvation.
.FUIPET
Animals. FAS-floxed mice have been described (24). RIPCre mice were
obtained from The Jackson Laboratory. We used 4- to 5-month-old male
and female littermate FASKO (Cre positive with the floxed allele) and WT
(Cre negative with the floxed allele) mice in a mixed (BL/6 and 129) background for experiments. FAS gene rearrangement was confirmed using
both PCR and Southern blotting, and mice were genotyped using FAS- and
Cre-specific primer sets (24). Animals were housed in temperature-con-
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trolled rooms with a 12-hour light/dark cycle with free access to standard and brains removed and processed. Ad libitum–feeding studies were also
mouse chow (Purina 5053) and water, unless otherwise specified. Protocols performed using a high-fat Western diet (fat content of 42%, TD88137;
followed NIH guidelines and were approved by the Washington University Harlan Teklad) (50). Food-intake data are expressed as a function of lean
body mass (g0.75).
Animal Studies Committee.
Locomotor activity and open-field behavior experiments. To determine norAnalytical and biochemical analyses. Measurements of serum glucose, free
mal cage activity in WT and FASKO mice, we used infrared sensors to fatty acids, triglycerides, cholesterol, insulin, and leptin concentrations,
detect body-heat image and its spatial displacement over time (InfraMot; body composition, and indirect calorimetry as well as glucose and insulin
TSE Systems). Sensors were mounted on standard mouse cage covers and tolerance tests were performed as described (24, 50). FAS enzyme activity
the data analyzed using the InfraMot software (version 1.3) to obtain from freshly harvested tissues and malonyl-CoA content from rapidly harduration and intensity of activity over several days. To evaluate locomo- vested, flash-frozen hypothalamus were assayed as described (24, 33).
tor activity and possible alterations in emotionality, mice were studied
Quantitative RT-PCR–based gene expression. RNA isolation, cDNA prepaover a 1-hour period while ambulations were measured over 24 hours in ration, and real-time quantitative PCR were performed as described
transparent (47.6 × 25.4 × 20.6 cm) polystyrene enclosures as described (24). Previously published oligonucleotide primer and TaqMan (Applied
(49). Each chamber was surrounded by a frame containing a 4 × 8 matrix Biosystems) probe sequences for ribosomal protein L32, glucokinase,
of photocell pairs, the output of which was analyzed by MotorMonitor Glut2, PPARα, ACO, and CPT-1a were used (24). The following primersoftware (Hamilton-Kinder). The software was used to define a 33 × 11 probe sets were used: Cre (forward: TGTTGCCGCGCCATCTG; reverse:
cm central zone and a peripheral or surrounding zone that was 5.5 cm TTGCTTCAAAAATCCCTTCCA; probe: CACCAGCCAGCTATCAACTCwide with the sides of the enclosure being the outermost boundary. This GCG), FAS (forward: TCCTGGAACGAGAACACGATCT; reverse: GAGAperipheral area extended along the entire perimeter of the chamber. Vari- CGTGTCACTCCTGGACTTG; probe: CTCACGCTGCGGAAACTTCAGables that were analyzed included the total number of beam breaks, ambu- GA-AATG), MCD (forward: AACATCCAGGGCATTGTGAAG; reverse:
lations (whole-body movements), rearings, entries made, time spent, and GCGGCGATCCTGTTCCT; probe: AGTGCCCTCCGACTGAAACCthe distance traveled in the center arena as well as the distance traveled GA), and Pdx-1 (forward: CGGCTGAGCAAGCTAAGGTT; reverse:
in the periphery surrounding the center. All behavioral experiments were TGGAAGAAGCGCTCTCTTTGA; probe: AGAATAACGAAAGGCGperformed between 8:00 am and noon by
an observer blinded to genotype.
Feeding studies. For acute experiments,
we measured food intake and body weight
over a 24-hour period in mice deprived of
food for 24 hours that were habituated
to the experimental setting (individually
housed mice in metabolic chambers) for at
least 7 days. Freely fed experimental mice
were also studied in these metabolic chambers to quantify food and water intake
and body weight after the acclimatization
'JHVSF
period. Another set of WT mice received an
)JHIGBUEJFU )'% JO85BOE'"4,0NJDF "BOE# &GGFDUPGXFFLTPGIJHIGBUEJFUPOGPPE
amount of food identical to that consumed JOUBLFBOEDIBOHFDPNQBSFEXJUIDIPXCBTFMJOFMFWFMT $ -FWFMTPGN3/"CZRVBOUJUBUJWF351$3
by the FASKO mice (pair fed) for a period PG11"3αBOEJUTUBSHFUHFOFT "$0 $15 BOE.$% JOUIFIZQPUIBMBNVTPG85BOE'"4,0
of 7 days. At the end of each experiment, NJDFBGUFSXFFLTPGIJHIGBUEJFU"MMSFTVMUTBSFNFBO4&.GPSmBOJNBMTQFSHSPVQ 1
animals were sacrificed, blood collected, DPNQBSFEXJUIDPSSFTQPOEJOH85MJUUFSNBUFT
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'JHVSF
"QSPQPTFENPEFMGPSUIFSPMFPGIZQPUIBMBNJD'"4BOE11"3α
JOUIFSFHVMBUJPOPGGFFEJOHCFIBWJPS'"4,0NJDFFYIJCJUBMFBO
IZQPQIBHJDQIFOPUZQFXJUIJNQBJSFEIZQPUIBMBNJD11"3αTJH
OBMJOH'"4JTSFHVMBUFECZNBOZGBDUPSTBTTPDJBUFEXJUIUIFGFE
TUBUFXIFSFBT11"3αJTJOEVDFEJOUIFGBTUFETUBUF"DUJWBUJPO
PG11"3αJOUIF$/4JOEVDFT$15BOE.$%FYQSFTTJPOBOE
EFDSFBTFTNBMPOZM$P"DPOUFOU UIFSFCZGPSNJOHBOJOUFHSBUJWF
TFOTPSZNPEVMFUPBGGFDUGFFEJOHIPNFPTUBTJT

GCTGTT-GGAGG). Coamplification of the mRNA for the mouse ribosomal protein L32, an invariant internal control, was performed in all
samples. Assays were performed in triplicate, and results normalized to
L32 mRNA levels.
In situ hybridization. Coronal hypothalamic sections (16 μm) were cut on a
cryostat and immediately stored at –80°C until hybridization. Oligos specific for FAS (5ʹ-GGGTCCATTGTGTGTGCCTGCTTGGGGTG-3ʹ), AgRP (5ʹCGACGCGGAGAACGAGACTCGCGGTTCTGTGGATCTAGCACCTC 3ʹ), NPY (5ʹ-GGGCGTTTTCTGTGCTTTCCTTCATTAAGAGGTCTG-3ʹ),
CART (5ʹ-ACAGTCACACAGCTTCCCGATCCTGGCCCCTTTC-3ʹ), POMC
(5ʹ-CTTGATGATGGCGTTCTTGAAGAGCGTCACCAGGGGCGTCTGGCTCTT-3ʹ), MCH (5ʹ-CCAACAGGGTCGGTAGACTCGTCCCAGCAT3ʹ), and orexin (5ʹ-TTCGTAGAGACGGCAGGAACACGTCTTCTGGCGACA-3ʹ) detection were used. These probes were 3ʹ end labeled with [α-35S]
2ʹ-deoxyadenosine-5ʹ-0-(1-thiotriphosphate) using terminal deoxynucleotidyl transferase (Amersham Biosciences). In situ hybridization was performed as described (32), using 8 animals per experimental group from 2
independent experiments.
Stereotaxic surgery and microinjection. Cannulae were implanted i.c.v. under
ketamine-xylazine anesthesia in WT and FASKO mice in the lateral ventricle (32). In other experiments, we implanted cannulae that were targeted
bilaterally to the ventral hypothalamus directed to stereotaxic coordinates
1.6 mm posterior to the bregma, ± 0.4 mm lateral to the midline, and 5.8
mm below the surface of the skull as previously described (6). After surgery,
animals were caged individually and allowed to recover for at least a week
prior to any experiments to ensure their body weight and food intake had
returned to baseline. Before Wy14,643 (Biomol) administration, 1 set of
animals was fasted for 23.5 hours (6:00 pm to 5:30 pm) and another maintained under ad libitum feeding conditions.
Previously 23.5-hour–fasted WT and FASKO mice received a single i.c.v.
injection of either Wy14,643 (15 μg dissolved in 2 μl of 20% dimethyl sulfoxide in artificial cerebrospinal fluid) or vehicle alone using a Hamilton
syringe. Thirty minutes after injection, at the start of the dark cycle, chow
was returned to the cages and food intake measured at 1, 2, 4, 12, and 24
hours. Body weight was measured immediately before the injection and at
each of the above time points. At the end of the 24-hour refeeding period,
each animal received an i.c.v. injection of 1 μl Evans blue dye (0.05% in artificial CSF) just before sacrifice. Only animals in which the dye was visualized within the third ventricle were included. We performed the study twice
with a crossover design in which animals that received the drug initially
also received a vehicle injection a week later.
Freely fed WT and FASKO mice received a single injection through
bilaterally implanted cannulae of either Wy14,643 (10 μg dissolved in
a total volume of 2 μl, i.e., 1 μl per side, of 20% dimethyl sulfoxide and
0.05% Evans blue dye in artificial CSF) or vehicle alone using a Hamil
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ton syringe. Thirty minutes after injection, at the onset of the dark cycle,
chow was returned to the cages and food intake measured at 4, 12, and
24 hours. Body weight was measured immediately before the injection
and at each of the above time points. At the end of the 24-hour feeding
period, animals were sacrificed, and the location of the cannulae was verified by noting the presence of Evans blue dye in the ventral hypothalamus.
Only animals in which the dye was visualized in the hypothalamus were
included in subsequent analyses.
β-galactosidase staining. FAS-floxed mice with and without Cre were
crossed with ROSA26 animals (The Jackson Laboratory) to assess the
distribution of Cre recombinase. Animals were deeply anesthetized with
i.p. injection of xylazine/ketamine cocktail and perfused with cold PBS,
followed by cold 0.1 M PBS containing 4% paraformaldehyde. Brain and
pancreas were dissected and fixed in 4% paraformaldehyde for 2 hours,
then washed in PBS. Pancreata were frozen in Tissue-Tex OCT (Triangle
Biomedical Sciences Inc.) compound. Brains were placed in 30% sucrose
overnight, then frozen in OCT. Coronal cryostat sections (10 μm) were
thaw mounted on slides, washed for 2 minutes in cold PBS, then placed
in detergent buffer (2 mM MgCl2, 0.01% sodium deoxycholate, 0.02% IGEPAL [Calbiochem] in PBS, pH 7.4) for 15 minutes at room temperature,
followed by staining solution (2 mM MgCl2, 0.01% sodium deoxycholate,
0.02% IGEPAL, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide in PBS, pH 7.4, containing 1 mg/ml of galactopyranoside dissolved in
dimethyl formamide) overnight at 37°C. Cells positive for β-galactosidase
indicated the presence of Cre.
Pancreas histomorphometry. From euthanized FASKO and WT animals, the
pancreas was dissected, fixed overnight in Bouin solution, embedded in
paraffin, and sectioned, and 5-μm sections were mounted on slides. Dual
immunofluorescence staining with anti-insulin (1:500; Sigma-Aldrich)
and a mixture of anti-glucagon (1:800; Chemicon International), antipancreatic polypeptide (1:40; Chemicon International), and anti-somatostatin (1:200; Dako) antibodies was performed and visualized using
the appropriate FITC and Texas red secondary antibodies (51). The β cell
mass was calculated by point-counting morphometry from a minimum of
6 insulin-stained sections (5 μm) separated by 200 μm from 3–4 animals
per genotype using the BIOQUANT Classic98 software package (version
3.50.6; BIOQUANT Image Analysis Corp.) as described (51).
Islet isolation and insulin secretion. Pancreatic islets from WT and FASKO
mice were isolated by collagenase digestion (52) and hand picked under a
microscope. Ten islets per condition were cultured with 3 mM or 20 mM
glucose, and insulin secreted in the medium was determined (52). Measurement of islet and whole pancreas insulin content was performed by
acid-ethanol extraction (51, 52).
Fatty acid oxidation. Finely minced (∼0.5 mm thick) liver slices (150 mg)
from freshly harvested livers of WT and FASKO mice were placed in 25-ml
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glass vials fitted with center wells containing 2 N NaOH and circular filter paper (1822-024; Whatman). Tissues were placed at the bottom of the
vials in 2 ml of Krebs-Ringer buffer (pH 7.4) with 0.4% BSA and 1 μCi (57
mCi/mmol) of 14C-palmitate (CFA-23; Amersham Biosciences). Vials were
capped with a rubber septum, and contents of the vial were gassed with
100% O2 for 10 minutes and incubated at 37°C for 2 hours on a rotatory
shaker (100 strokes/min). Then, 2 ml of 6 N HCl was injected to release
14CO . To ensure adequate transfer of 14CO to the NaOH-soaked filter
2
2
paper in the center well, vials were left undisturbed overnight at room
temperature. The filter paper was then transferred to scintillation fluid
and counted. The rates of fatty acid oxidation were calculated as pmoles of
14C-palmitate oxidized per hour per mg of tissue.
Statistics. Values are expressed as mean ± SEM. Statistical comparisons
were performed using an unpaired, 2-tailed Student’s t test (when 2
groups were analyzed) or ANOVA. If the overall F value was found to be
significant for the latter, comparisons between means were made using
appropriate post-hoc tests.
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